Puterizumab
Phase 2Monoclonal antibody
Puterizumab is one of 40 small molecule programs targeting Metastasis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
159 competitors in Metastasis
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Intron a
Merck & Co.Phase 3
PEG-Intron
Merck & Co.Phase 3
Herceptin
OOrganon and Co
Phase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Vascepa
AAmarin Pharma Inc.
Phase 3
Conmana
BBetta Pharmaceuticals Co., Ltd.
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Lenvima
EisaiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Puterizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SSir Run Run Shaw Hospital